Abstract
A 73-year-old man previously treated with rituximab for his mucosa-associated lymphoid tissue lymphoma suffered a suboptimal humoral immune response against an acquired SARS-CoV-2 infection. A detailed serological description revealed discrepant antigen-specific humoral immune responses. The titer of spike-targeting, “viral-neutralizing” antibodies remained below the detection level, in contrast to the anti-nucleocapsid, “binding” antibody response, which was comparable in both magnitude and kinetics. Accordingly, viral neutralizability and clearance was delayed, leading to prolonged RNAemia and persistent pneumonia. The present case highlights the need to closely monitor this unique population of recipients of B-cell-targeted therapies for their neutralizing antibody responses against SARS-CoV-2.
Keywords: COVID-19; SARS-CoV-2; neutralizing activity; persistent RNAemia; rituximab.
【저자키워드】 COVID-19, SARS-CoV-2, rituximab, Neutralizing activity, persistent RNAemia, 【초록키워드】 therapy, Pneumonia, antibody, SARS-COV-2 infection, Antibody Response, rituximab, Neutralizing activity, Kinetics, Viral, titer, lymphoma, immune responses, Neutralizing, humoral immune response, humoral immune responses, serological, Neutralizing antibody response, B-cell, mucosa-associated lymphoid tissue, recipients, recipient, clearance, MONITOR, Lymphoid tissue, highlight, remained, treated, unique, magnitude, suffered, comparable, 【제목키워드】 response, causing,